-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $129 at Jefferies
-
-
-
-
-
-
-
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
-
-
-
-
-
-
-
Insmed (INSM) Announces Publishing of Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC
-
-
-
-
-
-
-
Insmed Announces Presentations at the American Thoracic Society 2018 International Conference
-
-
15,923 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


